Penetration of moxifloxacin into peripheral compartments in humans.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsGender analysis of moxifloxacin clinical trialsMicrodialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.Pharmacokinetic study on pradofloxacin in the dog - comparison of serum analysis, ultrafiltration and tissue sampling after oral administrationFour-month moxifloxacin-based regimens for drug-sensitive tuberculosisMoxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions.A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infectionsIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.Tissue pharmacokinetics of levofloxacin in human soft tissue infections.Moxifloxacin in the treatment of skin and skin structure infections.Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansEfficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique).Dermal drug levels of antibiotic (cephalexin) determined by electroporation and transcutaneous sampling (ETS) technique.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose.Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.Microdialysis as a tool to determine the local tissue concentration of dicloxacillin in man.Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.
P2860
Q26827380-B5A1E3D2-AE28-40AB-83AF-8CF66787B1ACQ28538319-AF9F69E6-066C-414D-A425-EC91F8552553Q31046210-5569E9E7-97F4-4813-8789-0A24562167CEQ33554567-E3198053-44DB-4345-A86F-214F1884917BQ33812856-1934D754-6AC3-4C10-B4DC-8CF233ACA5E2Q33836578-A9C337EA-7563-4574-A790-9A2CCC52A105Q34142225-9376EE37-167F-4BDD-9C38-69371707F3DBQ34587450-102C8583-4D4A-4608-A112-AD86BDCEA071Q34777926-F35D109F-C467-4FBC-99A5-21ABC9072BFBQ34938184-E3C27753-AB13-48A4-897D-2DB95E50507EQ35023339-69CB1DF4-4C8A-41B1-BE92-971EECDBB33AQ35328383-FC80F8BE-BE6A-4ED5-A832-C97C6463E8AEQ35754443-47ABF426-EE53-4DC2-8534-1AC69F6062BAQ35825795-1169B60F-3F55-4AF5-9D11-C346F0A7C810Q35826148-4E15EBBF-E232-4421-83A0-010FEED45DABQ35919259-82E46B71-3BA3-47A7-946A-A4F3B15F48B9Q36047112-D8E4E8E9-0DEB-4D79-8678-FCDED97D496BQ36592698-E8C6DE14-B60F-471B-9DEE-A70DD9FAE485Q37183990-048B3570-C2F5-480D-90B1-42C1B2C515DAQ37335289-CBC21881-03B5-4EDC-9DF8-562A213A248AQ39456569-313E373B-1151-4E16-A52F-14257B8A78CEQ39475307-D91341B0-11EE-435C-9B8D-65917451DD70Q39715580-80C01988-CBD8-4762-936B-D2867C02F187Q40290562-65CC98C1-6713-4DFE-9071-01D5372F2F75Q40667360-53F6275F-4B48-4A47-898E-BDDE8709D83BQ41907641-5768691E-A40C-4EE0-BAB9-0CE341310FFEQ48361003-BD19D6F0-9AF2-4C14-BC56-039CDAA58976Q49548970-D4528AD8-3748-48FF-9252-B5EDA9044F90
P2860
Penetration of moxifloxacin into peripheral compartments in humans.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Penetration of moxifloxacin into peripheral compartments in humans.
@en
Penetration of moxifloxacin into peripheral compartments in humans.
@nl
type
label
Penetration of moxifloxacin into peripheral compartments in humans.
@en
Penetration of moxifloxacin into peripheral compartments in humans.
@nl
prefLabel
Penetration of moxifloxacin into peripheral compartments in humans.
@en
Penetration of moxifloxacin into peripheral compartments in humans.
@nl
P2093
P2860
P356
P1476
Penetration of moxifloxacin into peripheral compartments in humans
@en
P2093
P2860
P304
P356
10.1128/AAC.43.10.2345
P407
P577
1999-10-01T00:00:00Z